Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2011-04-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00028912

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Gastric Cancer
Gastrointestinal Carcinoid Tumor
Gastrointestinal Stromal Tumor
Ovarian Cancer
Peritoneal Cavity Cancer
Small Intestine Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2011-04-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 45

Registration Number: NCT00005049

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2011-03-28

Lead Sponsor: NYU Langone Health

Registration Number: NCT00025558

Locations: 🇦🇺
Princess Margaret Hospital for Children, Perth, Western Australia, Australia
🇺🇸
NYU Cancer Institute at New York University Medical Center, New York, New York, United States
🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States

and more 1 locations

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Cancer
Peritoneal Cavity Cancer

Interventions: Drug: carboplatin
Drug: pegylated liposomal doxorubicin hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2015-10-26

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 61

Registration Number: NCT00043082

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 88 locations

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: etoposide
Drug: exisulind

First Posted Date: 2003-01-27

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 41

Registration Number: NCT00041054

Locations: 🇺🇸
Broward General Medical Center, Fort Lauderdale, Florida, United States
🇺🇸
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States

and more 80 locations

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Primary Peritoneal Carcinoma
Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine Hydrochloride
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Topotecan Hydrochloride
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2003-01-27

Last Posted Date: 2019-04-16

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 4312

Registration Number: NCT00011986

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2019-06-04

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 571

Registration Number: NCT00003644

Locations: 🇺🇸
Fox Chase Cancer Center CCOP Research Base, Philadelphia, Pennsylvania, United States
🇺🇸
Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 148 locations

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Docetaxel
Drug: Herceptin

First Posted Date: 2003-01-27

Last Posted Date: 2016-11-15

Lead Sponsor: Sanofi

Target Recruit Count: 3222

Registration Number: NCT00021255

Locations: 🇻🇪
Sanofi-Aventis Administrative Office, Caracas, Venezuela

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Phase 3

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy
Drug: thalidomide

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 589

Registration Number: NCT00004859

Locations: 🇺🇸
Sletten Regional Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸
Doctors Hospital at Ohio Health, Columbus, Ohio, United States
🇺🇸
Swedish Covenant Hospital, Chicago, Illinois, United States

and more 230 locations

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00040872

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy